Assessing the Risk and Prognosis of Thrombotic Complications in Cancer Patients

摘要: � Context.—Cancer is characterized by the development of a prothrombotic state Approximately 15% to 20% and 1.5% 3.1% cancer patients develop venous arterial thrombosis, respectively, whereas 18% idiopathic events are caused an occult neoplasia. The highest risk observed in hematologic, gastrointestinal, lung malignancies, as well with active disease, especially first 3 months after diagnosis. Hospitalization, surgical interventions, implanted devices increase thrombotic risk. Patients metastatic febrile neutropenia, infections, severe comorbidities experience more frequently event. A contemporary prechemotherapy predictive model incorporates both clinical biologic parameters, such primary site, platelet count, white blood cell hemoglobin, use erythropoietic agents, body mass index. Several studies aim clarify prognostic value tissue factor, P-selectin, thrombin generation, microparticles, Ddimers. Objectives.—To summarize current views on epidemiology, factors, variables, discussing future perspectives existing limitations practice. Data Sources.—Review published literature, including review papers, epidemiologic studies, trials, online medical databases. Conclusions.—The thrombogenic properties tumor cells affect prognosis quality life for population. Despite improved awareness prompt thromboprophylaxis, recent reported increased rates events, annual risks thrombosis recurrence bleeding 21% 12%, respectively. factors parameters could allow patient stratification individualization anticoagulant treatment. (Arch Pathol Lab Med. 2013;137:1286–1295; doi: